In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

HSP70-molecular marker of cardioprotection in ischemic heart disease patients in physical rehabilitation

Session Poster Session 1

Speaker Nadezda Lyamina

Event : Heart Failure 2016

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Poster Session

Authors : N Lyamina (Saratov,RU), S Lyamina (Moscow,RU), E Kotelnikova (Saratov,RU), E Karpova (Saratov,RU), V Senvhikhin (Saratov,RU), T Lipchanskaya (Saratov,RU), E Bizyaeva (Saratov,RU)

N Lyamina1 , S Lyamina2 , E Kotelnikova1 , E Karpova1 , V Senvhikhin1 , T Lipchanskaya1 , E Bizyaeva1 , 1Saratov Scientific Research Institute of Cardiology - Saratov - Russian Federation , 2Moscow State University of Medicine and Dentistry - Moscow - Russian Federation ,

European Journal of Heart Failure Abstracts Supplement ( 2016 ) 18 ( Supplement 1 ), 99

Objective: assessment of cardioprotection effect formation by analyzing the relationship between HSP 70 level in ischemic heart disease (IHD) patients with documented ischemia and the value of myocardial ischemia index at the stage of physical rehabilitation. Material and methods: The study included 65 IHD patients (men and women) aged 39 – 65 y.o. (mean age 54.6+9.2 y.o.) with incomplete myocardial revascularization according to the results of percutaneous coronary intervention (PCI). Patients were included in the first 10 days after PCI. All patients performed 10-days course of daily controlled physical exercise (CPE) (up to 80% of maximal threshold load power) under ECG control, assessment of ischemia index, blood pressure and heart rate, and analysis of laboratory markers of myocardial injury (myoglobin, troponin, CK-MB, BNP - using immunofluorescent analyser Biosite Triage Meter Pro, Germany, and measurement of stress protein HSP70 with the use of laboratory diagnostics. ELISA on immunofluorescent analyser Stat. Fax USA. Safety and effectiveness of CPE were proved by study methods. Results: HSP70 analysis showed that in IHD patients before CPE HSP70 values varied depending on patients' clinical status and at first were determined firstly by the severity of ischemic manifestations (Spearman Rank Order Correlations (Data HSP70 and Ischemia Index.sta) MD pairwise deleted Marked correlations are significant at p < 0.05000. During diagnostics test stress-resistance was increased in all patients after CPE with 80% intensity from threshold load and it was accompanied by the elevated expression of inducible form of HSP70; this was documented by the significant decreasing of HSP70 level in systemic circulation. High correlation (r = 0.88406) was shown for HSP70 level and ishemic index interaction in IHD patients with inclimplete myocardial revasularization during physical rehabilitation with CPE based on ischemic preconditioning. At the same time the values of threshold ischemia were increased: maximum ST depression decreased, decreasing ECG leads with depression of ST  > 1 mm Hg and time to initial ST recovery, elevation of peak M in postexercise diagnostic stress-test. Increased induction of HSP70 proved elevation of physical activity threshold (stress-resistance) and cardioprotective effect on IHD patients; it was proved by HSP70 level in systemic circulation. Conclusion: Activation of proper intracellular system targeted for protection of cardiomyocytes from ischemia in IHD patients during CPE took place. This can be proved by increasing induction and expression of indusible HSP70 and can be used as molecular marker of cardioprotective effect in IHD patients.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are